InCarda Therapeutics Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$30M
- Investors
-
7
InCarda Therapeutics General Information
Description
Operator of a biopharmaceutical company intended to offer a novel approach to treating cardiovascular conditions and diseases. The company's lead treatment leverages the ability of inhaled therapy to deliver medicine in the first pass to cardiac tissue, presenting a small and effective dose of drug directly to affected regions of the heart, enabling doctors to treat paroxysmal atrial fibrillation and atrial arrhythmia in a simplified way.
Contact Information
Website
www.incardatherapeutics.comCorporate Office
- 39899 Balentine Drive
- Suite 185
- Newark, CA 94560
- United States
Corporate Office
- 39899 Balentine Drive
- Suite 185
- Newark, CA 94560
- United States
InCarda Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series C) | 21-Oct-2020 | $30M | Completed | Clinical Trials - Phase 3 | ||
| 4. Later Stage VC (Series B) | 20-Nov-2018 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series A) | 28-Apr-2015 | Completed | Clinical Trials - General | |||
| 2. Later Stage VC (Series A) | 17-Dec-2014 | $567K | $877K | Completed | Generating Revenue | |
| 1. Angel (individual) | 01-Oct-2012 | $310K | $310K | Completed | Generating Revenue |
InCarda Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B2 | ||||||||
| Series B1 | 39,656,993 | $0.001000 | $0.04 | $0.46 | $0.46 | 1x | $0.46 | 18.36% |
| Series A | 18,844,440 | $0.001000 | $0.03 | $0.38 | $0.38 | 1x | $0.38 | 8.72% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
InCarda Therapeutics Comparisons
Industry
Financing
Details
InCarda Therapeutics Competitors (28)
One of InCarda Therapeutics’s 28 competitors is Acesion Pharma, a Venture Capital-Backed company based in Frederiksberg, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Acesion Pharma | Venture Capital-Backed | Frederiksberg, Denmark | ||||
| Cardurion | Venture Capital-Backed | Burlington, MA | ||||
| Grace Therapeutics | Corporation | Princeton, NJ | ||||
| DalCor Pharmaceuticals | Venture Capital-Backed | Montreal, Canada | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA |
InCarda Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
InCarda Therapeutics Patents
InCarda Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4444417-A1 | Inhaled therapy for cardiac arrhythmia | Pending | 09-Dec-2021 | ||
| CA-3204054-A1 | Inhalable imatinib formulation | Pending | 06-Jan-2021 | ||
| US-20220226301-A1 | Kits and methods for induction of cardioversion in subjects with atrial arrhythmias | Active | 17-Dec-2020 | ||
| US-20230226032-A1 | Kits and methods for induction of cardioversion in subjects with atrial arrhythmias | Pending | 17-Dec-2020 | ||
| CA-3200432-A1 | Kits and methods for induction of cardioversion in subjects with atrial arrhythmias | Pending | 17-Dec-2020 | A61K31/4458 |
InCarda Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
InCarda Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Innoviva | Corporation | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| HealthCap | Venture Capital | Minority | ||
| Sofinnova Investments | Venture Capital | Minority | ||
| Asset Management Ventures | Venture Capital | Minority |
InCarda Therapeutics FAQs
-
When was InCarda Therapeutics founded?
InCarda Therapeutics was founded in 2009.
-
Where is InCarda Therapeutics headquartered?
InCarda Therapeutics is headquartered in Newark, CA.
-
What is the size of InCarda Therapeutics?
InCarda Therapeutics has 15 total employees.
-
What industry is InCarda Therapeutics in?
InCarda Therapeutics’s primary industry is Drug Discovery.
-
Is InCarda Therapeutics a private or public company?
InCarda Therapeutics is a Private company.
-
What is the current valuation of InCarda Therapeutics?
The current valuation of InCarda Therapeutics is .
-
What is InCarda Therapeutics’s current revenue?
The current revenue for InCarda Therapeutics is .
-
How much funding has InCarda Therapeutics raised over time?
InCarda Therapeutics has raised $77.9M.
-
Who are InCarda Therapeutics’s investors?
Innoviva, Deerfield Management, HealthCap, Sofinnova Investments, and Asset Management Ventures are 5 of 7 investors who have invested in InCarda Therapeutics.
-
Who are InCarda Therapeutics’s competitors?
Acesion Pharma, Cardurion, Grace Therapeutics, DalCor Pharmaceuticals, and Renova Therapeutics are some of the 28 competitors of InCarda Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
